GSK-3β activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross-sectional study.
Yang GaoHaitao YuYanchao LiuZhipeng XuBenrong HeHonghai LiuJian-Zhi WangYao ZhangYi LiangYing YangJie ZhengJian-Zhi WangPublished in: Journal of diabetes (2023)
We reported here that the upregulation of GSK-3β activity mediates the exacerbation of cognitive impairment by ApoE ε4-enhanced cognitive impairment in T2DM patients, suggesting GSK-3β inhibitors as promising drugs for preserving cognitive function in T2DM patients, especially to those with ApoE ε4 genotype.
Keyphrases
- cognitive impairment
- end stage renal disease
- signaling pathway
- newly diagnosed
- chronic kidney disease
- ejection fraction
- prognostic factors
- chronic obstructive pulmonary disease
- pi k akt
- cognitive decline
- adipose tissue
- clinical trial
- type diabetes
- skeletal muscle
- poor prognosis
- insulin resistance
- cross sectional
- long non coding rna
- mechanical ventilation
- glycemic control